Regulatory watch

Impact of scientific advice from the European Medicines Agency

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Impact of scientific advice.


The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.

Author information



Corresponding author

Correspondence to Jan Regnstrom.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (box)

Definitions and data analysis (PDF 140 kb)

Supplementary information S2 (table)

Summary of MAA submissions, SA requests and compliance with SA by year (PDF 107 kb)

Supplementary information S3 (table)

MAA procedure time and the number of MOs in relation to compliance with SA on clinical trial design (PDF 97 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hofer, M., Jakobsson, C., Zafiropoulos, N. et al. Impact of scientific advice from the European Medicines Agency. Nat Rev Drug Discov 14, 302–303 (2015).

Download citation

Further reading


Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing